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Abstract  49 
Background: Practice patterns for the management of urinary retention (UR) secondary to 50 
benign prostatic obstruction (BPO) (UR/BPO) vary widely and remain unstandardized. 51 
Objective: To review the evidence for managing patients with UR/BPO with pharmacological 52 
and non-pharmacological treatments included in the European Association of Urology 53 
Guidelines on Non-neurogenic Μale lower urinary tract symptoms. Evidence acquisition: 54 
Search was conducted using CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and WHO 55 
ICTRP; searched up to 22 April 2018. This systematic review included randomized control 56 
trials (RCTs) and prospective comparative studies. Methods as detailed in the Cochrane 57 
Handbook were followed. Certainty of evidence (CoE) was assessed using GRADE approach. 58 
Evidence synthesis: Literature search identified 2,074 citations. Twenty-one studies were 59 
included (qualitative synthesis). The evidence for managing patients with UR/BPO with 60 
pharmacological or non-pharmacological treatments is limited. CoE for most outcomes was 61 
low/very low. Only α1-blockers (alfuzosin, tamsulosin) have been evaluated in over one RCT. 62 
Pooled results indicated that α1-blockers provided significantly higher successful trial without 63 
catheter (TWOC) rates compared to placebo [alfuzosin:322/540 (60%) vs 156/400 (39%) (OR 64 
2.28, 95%CI 1.55 to 3.36;participants=940;studies=7;I2=41%;low CoE); tamsulosin:75/158 65 
(47%) vs 40/139 (29%) (OR 2.40, 95%CI 1.29 to 4.45;participants=297; studies=3;I2=30%;low 66 
CoE)] with rare adverse events. Similar rates were achieved with tamsulosin or alfuzosin [51/87 67 
(59%) vs 45/84 (54%) (OR 1.28, 95%CI 0.68 to 2.41; participants=171;studies=2;I2=0%;very 68 
low CoE)]. Non-pharmacological treatments have been evaluated in RCTs/prospective 69 
comparative studies only sporadically. 70 
Conclusions: There is some evidence that usage of α1-blockers (alfuzosin and tamsulosin) may 71 
improve resolution of UR/BPO. As most non-pharmacological treatments have not been 72 
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evaluated in patients with UR/BPO, the evidence is inconclusive about benefits and harms. 73 
Patient summary: There is some evidence that alfuzosin and tamsulosin may increase 74 
successful trial without catheter rates but little or no evidence on various non-pharmacological 75 
treatment options for managing patients with urinary retention secondary to benign prostatic 76 
obstruction.  77 
 78 
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1. Introduction 97 
Urinary retention (UR) is the inability of a patient to completely or partially empty the bladder 98 
by voluntary micturition. UR can be acute or chronic. Acute UR (AUR) is defined as a painful, 99 
palpable or percussible bladder, when the patient is unable to pass any urine [1, 2]. Chronic UR 100 
(CUR) is defined as a non-painful bladder, which remains palpable or percussible after the 101 
patient has passed urine [1, 2]. The term implies a significant post void residual urine volume 102 
(PVR); a minimum figure of 300mL has been mentioned [1, 2]. Nevertheless, the exact 103 
definitions of AUR and CUR remain controversial [3]. The exact incidence of UR in the general 104 
population remains unclear with various estimates suggested from 2.2 to 6.8 events/1,000 105 
patient-years [4, 5]. Benign prostatic obstruction (BPO) is considered the most prevalent cause 106 
of UR in men [5].  107 
Several α1-adrenoceptor antagonists (α1-blockers) have been tested in patients with AUR to 108 
increase successful trial without catheter (TWOC) rates; including  alfuzosin [6-8], tamsulosin 109 
[6, 9] and silodosin [10], most of which demonstrate a higher success compared to placebo. The 110 
alfuzosin in AUR (ALFAUR) study, the largest clinical trial to date, evaluated the role of 111 
alfuzosin 10mg OD administrated 2-3 days before TWOC and showed that alfuzosin almost 112 
doubled the successful TWOC rate [11]. Since most patients having a successful TWOC have 113 
no AUR relapse in the short-term, administration of an α1-blocker before catheter withdrawal 114 
is considered a valuable treatment [12]. It has been reported that >80% of patients who did not 115 
receive any treatment after an AUR episode were submitted to surgery within 5 years [13]. As 116 
a result, pharmacological intervention should be considered not only an aid to increase the 117 
successful TWOC chance, but also a mean to reduce AUR recurrence risk, which could lead to 118 
further interventions in the long-term. Data from five studies, which evaluated the long-term 119 
use of α1-blockers showed that patients receiving α1-blockers had significantly lower risk of 120 
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recurrent AUR [14]. The use of 5α reductase inhibitors (5ARIs) as a combination therapy with 121 
α1-blockers in AUR treatment is still controversial [15, 16]. Urgent prostatic surgery is another 122 
therapeutic option for AUR,  however with a higher risk of intra-operative and/or postoperative 123 
complications, and mortality compared to elective surgery [17]. Therefore, elective surgery is 124 
the treatment of choice for most men who fail TWOC. Increased perioperative morbidity is also 125 
associated with presence of indwelling urinary catheter in cases operated after TWOC failure 126 
[18].  127 
Management of UR secondary to BPO (UR/BPO) varies widely. Relevant systematic reviews 128 
(SRs) are scarce [19-21]. The European Association of Urology (EAU) Non-neurogenic Male 129 
lower urinary tract symptoms (LUTS) Guidelines Panel acknowledges the current lack of high 130 
certainty evidence (CoE), the growing scientific base, and cites the need to understand more 131 
about management options. This SR is a product of this panel and compared the effectiveness 132 
of various treatment options currently available for patients with UR/BPO. The objective was 133 
to address these questions: 134 
• What are the benefits of treatments for UR (AUR or CUR) in adults with BPO? 135 
• What are the harms of treatments for UR (AUR or CUR) in adults with BPO? 136 
2. Evidence acquisition 137 
Randomized controlled trials (RCTs); quasi-RCTs (QRCTs) and prospective comparative 138 
studies were included. Any other studies were excluded, such as: non-comparative studies, 139 
retrospective studies, and case series. Studies were included only if:   140 
• UR (AUR or CUR)/BPO was addressed as a study outcome  141 
• A sub-analysis (or post-hoc analysis) on participants presenting with UR (AUR or 142 
CUR)/BPO was reported  143 
• Pharmacological treatment had been evaluated in an RCT or QRCT setting 144 
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• Non-pharmacological treatment had been evaluated in an RCT, QRCT or prospective 145 
comparative setting 146 
• At least one of the primary or secondary outcomes of this SR was reported.  147 
Adult men (≥18 years) with UR (AUR or CUR defined as persistently elevated PVR 148 
≥300mL)/BPO were included. Individuals with UR attributed to drug side effects, 149 
pharmacological/non-pharmacological procedures; suspected or confirmed urethral/bladder 150 
pathology (such as malignancy, urethral stricture, bladder neck contracture, bladder stones, 151 
neurogenic bladder, and infection/inflammation) or prostate cancer were excluded.  152 
The following comparisons of intervention vs comparator were investigated:  153 
Intervention: 154 
Any pharmacological or non-pharmacological treatment included in the EAU Guidelines on 155 
Non-neurogenic Μale LUTS (2018), as defined below: 156 
• Pharmacological treatment (monotherapy or combination therapy): α1-blockers, 5ARIs, 157 
phosphodiesterase 5 inhibitors (PDE5Is), plant extracts (phytotherapy)  158 
• Non-pharmacological treatment: any kind of instrumental intervention (surgical 159 
treatment; such as transurethral resection of the prostate (TURP)), including suprapubic 160 
catheterization (SPC) or urethral catheterization irrespective of duration prior to TWOC 161 
• Any combination of the above pharmacological and non-pharmacological treatments 162 
Comparator: 163 
• No treatment  164 
• Placebo or sham treatment 165 
• Any pharmacological or non-pharmacological treatment, as defined above (any 166 
comparison within intervention was accepted such as comparison of different 167 
pharmacological treatments, and/or comparison of different types of catheterization) 168 
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We performed a broad search of the Core Outcome Measures in Effectiveness Trials (COMET) 169 
database (http://www.comet-initiative.org/) for a core outcome set (COS) using the term 170 
“Urology” in the disease category. No directly applicable COS existed for the disease or 171 
treatments dealt in this SR. Therefore, the EAU guideline panel reached consensus on what they 172 
regarded as most important outcomes for this condition. No patient advocates or other 173 
stakeholders were involved in the consensus process. 174 
The primary benefit outcomes were:  175 
• Successful TWOC rate as defined by trials in each single study 176 
• UR (AUR or CUR) recurrence rate following a successful TWOC 177 
The primary harm outcomes were:  178 
• Harms of treatment for UR (AUR or CUR) including any adverse effects reported (such 179 
as death, pharmacological/non-pharmacological treatment complications). Surgical 180 
complications occurring up to 1 month postoperatively, which were specifically graded 181 
according to the modified Clavien classification system [22, 23]. 182 
The secondary outcomes included:  183 
• Maximum flow rate (Qmax), International Prostate Symptom Score (IPSS) questionnaire 184 
results (including Quality of Life (QoL) score) and PVR; absolute values and changes 185 
from baseline at each follow up time point 186 
• Specific measures for evaluating non-pharmacological treatment (operation duration, 187 
bladder irrigation duration, postoperative catheterization and hospitalization duration) 188 
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 189 
approach was used to assess CoE for each comparison [24]. CoE of outcomes considered 190 
critical/important from patients’ perspective in decision-making was rated on study design, 191 
limitations in study design/execution (risk of bias (RoB)), inconsistency of results, indirectness 192 
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of evidence, imprecision and publication bias. Final decision on the selection of the outcomes 193 
to be rated was based on a consensus among the SR authors. We used the GRADEpro Guideline 194 
Development Tool (GDT) to assess the CoE of the critical and important outcomes. Summary 195 
of findings (SoF) tables are available as supplementary material (SM), and following outcomes 196 
were chosen, listed according to priority: 197 
• Successful TWOC rate (at 1 month after the intervention) 198 
• Modified Clavien classification system grade ≥3 (at 1 month after the intervention) 199 
• UR (AUR or CUR) necessitating additional pharmacological or non-pharmacological 200 
intervention rate following successful TWOC (at 12 months after the intervention) 201 
• IPSS score (at 12 months after the intervention) 202 
• QoL score (at 12 months after the intervention) 203 
The literature was systematically searched in accordance with the Preferred Reporting Items 204 
for Systematic Reviews and Meta-analyses (PRISMA) statement [25, 26]. We followed the 205 
methodology as detailed in the Cochrane Handbook for Systematic Reviews of Interventions 206 
[27]. Search strategies are available (SM 1).  207 
The following electronic databases were searched up to April 22, 2018: 208 
• The Cochrane library databases (Cochrane Central Register of Controlled Trials 209 
<March 2018>, Cochrane Database of Systematic Reviews <2005 to April 18, 2018>)  210 
• Medline (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 211 
MEDLINE(R) <1946 to April 2018>);  212 
• Embase (OvidSP <1974 to April 2018>)  213 
Hand searches of the following trial registers/websites were also performed: 214 
• ClinicalTrials.gov (https://clinicaltrials.gov/) 215 
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• World Health Organization International Clinical Trials Registry Platform (WHO 216 
ICTRP; http://www.who.int/ictrp/en/)  217 
• For new(er) pharmacological compounds manufacturers' websites, Food and Drug 218 
Administration (FDA) and European Medicines Agency (EMA) websites were searched 219 
(no restriction on date of publication) 220 
Other potentially eligible studies were searched for using reference lists of included studies, 221 
other SRs/health technology assessment reports. Search was supplemented by manually 222 
searching the reference list of the EAU Guidelines on Non-neurogenic Μale LUTS.  223 
Two review authors (MK, IK) independently scanned the title, abstract content, or both, of 224 
every record retrieved to determine which studies should be assessed further, extracted all data 225 
and assessed RoB of each included study. Any disagreements were resolved through consensus 226 
or by consultation with a third author (CM). RoB in RCTs was assessed using the Cochrane 227 
“RoB” assessment tool [27, 28]. “RoB” domains were judged as either low, high, or unclear 228 
risk [27]. RoΒ in non-randomized comparative studies was assessed using all the domains of 229 
Cochrane RoB tools [29]. In addition, a list of the six most important potential confounders for 230 
harm and benefit outcomes were developed a priori with clinical content experts (EAU Non-231 
neurogenic Male LUTS Guidelines Panel): 1) age, 2) severity of LUTS (IPSS score), 3) prostate 232 
volume, 4) active and previous medical treatment for BPO, 5) prior history of UR and 6) history 233 
of prostatic infection. When at least two included trials were available for comparison of a given 234 
binary/dichotomous/categorical benefit or harm outcome, data were expressed as odds ratio 235 
(OR) with 95% confidence interval (CI) and p value where available. For continuous outcomes 236 
measured on the same scale, the intervention effect was estimated using mean difference (MD; 237 
(95%CI)). Meta-analysis was performed where there was more than one RCT reporting the 238 
same outcome. In the event of substantial clinical/methodological heterogeneity, trial results 239 
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were not reported as pooled effect estimate. Heterogeneity was identified by visually inspecting 240 
forest plots and by using a standard Chi² test with a significance level of α=0.1. In view of the 241 
low power of this test, I² statistic was also considered, which quantifies inconsistency across 242 
trials to assess heterogeneity impact on the meta-analysis [30]. Heterogeneity was dealt as 243 
suggested in the Cochrane Handbook for Systematic Reviews of Interventions [27].   244 
The protocol of the present SR was published on PROSPERO (SM 2). 245 
3. Evidence synthesis  246 
A total of 21 studies (18 RCTs [6-11, 31-42] and three prospective comparative studies [43-45]) 247 
were included. Figure 1 illustrates literature flow. Table 1 presents baseline characteristics of 248 
included studies. RoB assessment is illustrated in Fig. 2.  249 
3.1 Pharmacological treatments 250 
Among the pharmacological treatments included in the EAU Guidelines on Non-neurogenic 251 
Μale LUTS, only α1-blockers (alfuzosin, tamsulosin, silodosin, doxazosin) and the PDE5I 252 
sildenafil have been evaluated for treating patients with UR/BPO in RCTs. No RCT addressing 253 
results on any other pharmacological treatment (monotherapy or combination therapy) included 254 
in the EAU Guidelines on Non-neurogenic Μale LUTS such as 5ARIs (finasteride, dutasteride) 255 
was detected. 256 
Alfuzosin was compared to placebo in seven RCTs [6-8, 11, 31, 34, 38]. Pooled results 257 
indicated that alfuzosin provided significantly higher successful TWOC rates compared to 258 
placebo; 322/540 (60%) vs 156/400 (39%) (OR 2.28, 95%CI 1.55 to 3.36; 259 
participants=940;studies=7;I2=41%;low CoE; Fig. 3). Adverse events were generally rare, most 260 
commonly including dizziness, headache and orthostatic hypotension, without difference 261 
between arms. Tamsulosin was compared to placebo in three RCTs [6, 9, 34]. In two of them, 262 
patients were randomized to three arms (tamsulosin vs. alfuzosin vs. placebo) [6, 34]. Pooled 263 
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results indicated that tamsulosin provided significantly higher successful TWOC rates 264 
compared to placebo; 75/158 (47%) vs 40/139 (29%) (OR 2.40, 95%CI 1.29 to 265 
4.45;participants=297;studies=3;I2=30%;low CoE; Fig. 4) but similar rates compared to 266 
alfuzosin; 51/87 (59%) vs 45/84 (54%) (OR 1.28, 95%CI 0.68 to 2.41; 267 
participants=171;studies=2;I2=0%;very low CoE). Tamsulosin was also compared to 268 
tamsulosin/alfuzosin combination in one RCT [33] and tamsulosin/sildenafil combination in 269 
another RCT [37]. No difference between monotherapy vs tamsulosin/alfuzosin combination 270 
was detected regarding successful TWOC rates; 11/35 (31%) vs 14/35 (40%) (OR 0.69, 95%CI 271 
0.26 to 1.84;participants=70;studies=1;very low CoE). Most common adverse events in the 272 
combination arm included dizziness, headache and retrograde ejaculation, which were not 273 
significantly higher than those in the monotherapy arm [33]. Tamsulosin/sildenafil combination 274 
was also similar to monotherapy regarding successful TWOC rates; 41/50 (82%) vs 37/51 275 
(73%) (OR 1.46, 95%CI 0.66 to 3.25;participants=101;studies=1;very low CoE) [37]. Three-276 
day vs 7-day tamsulosin treatment for AUR was compared in one RCT [32]. No significant 277 
difference in successful TWOC rates; 18/30 (60%) vs 21/30 (70%) (OR 0.64, 95%CI 0.22 to 278 
1.87;participants=60;studies=1;very low CoE). Silodosin was compared to placebo in one RCT, 279 
showing a significantly higher successful TWOC rate at 3 days: 23/30 (77%) vs 11/30 (37%) 280 
(OR 5.68, 95%CI 1.84 to 17.5;participants=60;studies=1;very low CoE) [10]. Silodosin was 281 
also compared to tamsulosin in one RCT showing no significant differences in successful 282 
TWOC rates: 48/80 (60%) vs 54/80 (68%) (OR 1.44, 95%CI 0.76 to 283 
2.71;participants=160;studies=1;very low CoE) or complication rates between arms [35]. 284 
Doxazosin was compared to no medication in one RCT showing no difference in successful 285 
TWOC rates: 13/22 (59%) vs 13/24 (54%) (OR 1.22, 95%CI 0.38 to 286 
3.93;participants=46;studies=1;very low CoE) [36].  287 
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3.2 Non-pharmacological treatments 288 
Very few non-pharmacological treatment options included in the EAU Guidelines on the 289 
management of Non-neurogenic Μale LUTS have been evaluated for managing patients with 290 
UR/BPO in RCTs/prospective comparative studies. None of them has been evaluated in more 291 
than one trial. An international multicentre RCT evaluated bipolar TURP (B-TURP) vs 292 
monopolar TURP (M-TURP) in 279 patients with BPO [40, 46-48]. A sub-analysis [46, 47] 293 
and post hoc analysis (SM 3) on patients presenting with UR (B-TURP: n=50; M-TURP: n=63) 294 
revealed no difference between arms either for successful TWOC rates: 47/50 (94%) vs 57/63 295 
(90%) (OR 1.65, 95%CI 0.39 to 6.95;participants=113;studies=1;low CoE) or for any of the 296 
outcomes of interest of this SR. In a RCT comparing transurethral microwave thermotherapy 297 
(TUMT) to TURP or open prostatectomy in patients with UR, no difference was detected in 298 
successful TWOC rates between arms: 48/61 (79%) vs 52/59 (88%) (OR 0.58, 95%CI 0.22 to 299 
1.52;participants=120;studies=1;very low CoE) [41]. More complications were seen in 300 
TURP/enucleation arm. The efficacy of bladder training before catheter removal was evaluated 301 
in one RCT on patients with a first episode of AUR secondary to BPO randomized to 302 
pharmacological treatment (combination of tamsulosin 0.2mg/finasteride 5mg OD) with free 303 
catheter drainage for 7 days (n=405) or pharmacological treatment combined with bladder 304 
training (n=440) prior to TWOC [42]. Similar successful TWOC rates: 190/405 (47%) vs 305 
187/440 (43%) (OR 0.84, 95%CI 0.64 to 1.10;participants=840;studies=1;moderate CoE) and 306 
adverse event rates were observed in both arms. Transurethral catheterization vs SPC in patients 307 
with AUR was assessed in a prospective comparative study [44]. Thirty patients received 308 
transurethral catheterization and 56 patients received SPC (12F Cystofix). Patients were 309 
followed up for 3 years. TWOC failure was observed in seven out of 11 patients (64%) in the 310 
transurethral group vs seven out of 22 patients (32%) in the SPC group. Complication rates 311 
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were notably higher in the transurethral group (urinary tract infections (UTIs): 12 out of 30 312 
patients; 40% vs 10 out of 56 patients;18% and urethral strictures: five out of 30 patients; 17% 313 
vs none out of 56 patients;0.0%). Dislodgement was the only complication repeatedly 314 
associated with SPC;13 patients (23%;11 of these patients needed catheter replacement) vs one 315 
patient (3.4%), potentially necessitating a more secure form of catheter fixation such as a Foley 316 
catheter placement through a suprapubic introducer. Finally, our search criteria revealed an old 317 
study from 1993, comparing prostatic spiral (Uromed) to prostatic stent (Urolume) regarding 318 
effectiveness and complications [43]. Detailed results are available as SM 3-4. SoF tables 319 
summarizing CoE assessment based on the GRADE approach are available as SM 5. 320 
4. Discussion 321 
The evidence for managing patients with UR/BPO with pharmacological or non-322 
pharmacological treatments is limited. CoE for most outcomes was low or very low. All 323 
selective α1-blockers (alfuzosin, tamsulosin and silodosin) appear to be superior to placebo in 324 
terms of successful TWOC rates after a short period of catheterization [6, 7, 9-11, 31, 34, 38]. 325 
In contrast, no benefit has been revealed with the use of the non-selective α1-blocker doxazosin 326 
and adding sildenafil to tamsulosin does not offer additional benefit compared to tamsulosin 327 
monotherapy but these studies are under powered, CoE is very low and therefore no definite 328 
conclusions can be drawn for these comparisons [36, 37]. Pooled results indicate that alfuzosin 329 
and tamsulosin monotherapy provide significantly higher successful TWOC rates compared to 330 
placebo with rare adverse events. Similar successful TWOC rates are achieved with alfuzosin 331 
or tamsulosin. Non-pharmacological treatments have been evaluated in RCTs/prospective 332 
comparative studies only sporadically. 333 
B-TURP and TUMT have both been tested against M-TURP and found to have comparable 334 
efficacy/safety for the management of patients with UR according to the authors of these studies 335 
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[40, 41, 46-48] but this conclusion should be interpreted with caution. SPC appears to safeguard 336 
against some of the potential complications of urethral catheterization such as UTI and urethral 337 
stenosis, allowing assessment of spontaneous voiding and avoiding re-catheterization after a 338 
failed attempt [44]. Although it has been suggested that SPCs might be associated with lower 339 
rates of UTI and urethral stricture formation, less patient discomfort, and easier management; 340 
a Cochrane SR failed to demonstrate lower risk of symptomatic UTIs with use of SPC [49]. 341 
Three-day rather than 7-day period of catheterization after a first episode of AUR in addition 342 
to α1-blocker treatment should be preferred since longer catheterization times increase the 343 
complication rates without increasing significantly TWOC success [32]. A short period of 344 
intermittent self-catheterization might be beneficial to maximize recovery of bladder function 345 
before TURP and should be preferred over indwelling catheterization in case of delayed surgery 346 
as it is associated with less infectious complications [32, 36]. 347 
A SR on the management of AUR including pharmacological and non-pharmacological 348 
treatment options, recommended use of α1-blockers before TWOC, discouraging emergency 349 
operative management [21]. SPC over indwelling catheter use was debatable and 350 
catheterization duration was controversial but <3 days appeared to be a safe option in avoiding 351 
catheterization-related complications [21]. Although TURP remained the gold standard, there 352 
was emergence of newer operative management utilizing laser techniques [21]. Nevertheless, 353 
conclusions were limited due to low CoE [21].  354 
In another SR, the effectiveness and comparative effectiveness of pharmacological and non-355 
pharmacological treatments for CUR were evaluated [19]. A total of 11 studies (RCTs and 356 
prospective cohort studies) enrolling patients with CUR were included. Results were analyzed 357 
by etiology: obstructive, non-obstructive, and mixed populations/unknown causes. Only three 358 
studies addressed obstructive causes of CUR. Low quality evidence suggested that TURP and 359 
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TUMT achieved similar improvements in successful TWOC rates at 6 months post-treatment. 360 
Evidence was insufficient to draw conclusions regarding other outcomes. Evidence for other 361 
treatment comparisons for CUR from obstructive causes was insufficient to conclude that one 362 
treatment was more effective than the comparison. Evidence on harms was inconsistently 363 
reported across all interventions, and no differences were detected across treatment groups; 364 
however, studies were not adequately powered to detect differences in harms across groups. 365 
Further studies of patients with CUR are needed. 366 
A Cochrane SR assessed α1-blocker effectiveness on successful resumption of micturition 367 
following removal of urethral catheter after an episode of AUR in men [20]. Nine RCTs were 368 
included. There was moderate CoE to suggest that successful TWOC rates favored α1-blockers 369 
over placebo. The incidence of recurrent AUR was lower in groups treated with α1-blockers. 370 
CoE was moderate favoring alfuzosin, tamsulosin and silodosin, but not doxazosin. Of the trials 371 
mentioning adverse effects, there was not enough information to detect statistically significant 372 
differences between groups and CoE was low. Overall, adverse effect rates were low for both 373 
placebo and α1-blockers [20]. 374 
4.1 Strengths and limitations of this SR 375 
The major strengths are: 376 
• Performed a comprehensive literature search  377 
• Adopted a robust/transparent methodological approach based on Cochrane Handbook 378 
• Assessed CoE with the GRADE approach 379 
The principal limitations are: 380 
• Although every effort was made following strict/specific trial exclusion criteria to 381 
exclusively include trials summarizing results from individuals with UR/BPO, the slight 382 
possibility of including few patients with neurological/bowel conditions-/detrusor 383 
  
17 
 
underactivity-associated UR or even few patients without (urodynamically proven) 384 
BPO cannot be completely ruled out since access on raw individual patient data was not 385 
possible  386 
• Significant heterogeneity among identified studies 387 
• Included studies had a relatively small number of participants, short follow up and 388 
methodological flaws with inadequate reporting. Although authors were contacted for 389 
information whenever needed, the majority did not reply as usual in real life. Therefore, 390 
following the guidelines of the Cochrane Handbook, many RoB domains were judged 391 
as unclear i.e. insufficient information to permit judgment. 392 
4.2 Recommendations for the future research: 393 
• Several contemporary non-pharmacological treatment options included in the EAU 394 
Guidelines on the Management of Non-neurogenic Male LUTS were not assessed in 395 
this SR based on the inclusion criteria. For example, no comparative studies evaluating 396 
holmium, greenlight or thulium laser were detected. This represents a significant gap in 397 
the literature. Such a lack of evidence needs to be addressed by future studies since the 398 
subpopulation of UR patients is unique, harvesting specific perioperative risk factors. 399 
• Further studies on CUR are needed as well as on 5ARIs after successful TWOC would 400 
be logical-as these, and not α1-blockers, have been shown to reduce AUR rates.  401 
• Previous UR is a well-established risk factor for ongoing AUR episodes. Older data 402 
indicated that only 16% of patients presenting with UR had remained catheter-free for 403 
a period of 5 years [13]. According to the EAU Guidelines on the Management of Non-404 
neurogenic Male LUTS, surgical treatment is usually required when patients have 405 
experienced among others recurrent/refractory UR or overflow incontinence (absolute 406 
operation indication, need for surgery) [50]. Nevertheless, future studies which will help 407 
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to reliably identify which patients could respond to prolonged medical treatment and 408 
which should be scheduled for prompt or elective surgery are deemed necessary. 409 
• The optimum treatment management for frail patients with significant comorbidities in 410 
the long-term remains poorly documented, at least from the respect of studies directly 411 
comparing different treatment modalities (e.g. surgery vs long-term catheterization). 412 
Future research should focus on this area. 413 
• The observed heterogeneity of TWOC success definitions among studies has not only 414 
important impact on the assessment of treatment outcomes but also renders adoption of 415 
a universally-accepted definition of TWOC success necessary in future studies.  416 
• CoS should be developed for UR/BPO, by following the COMET initiative. 417 
• Future studies should be adequately powered/follow the principle/recommendation of 418 
Consolidated Standards of Reporting Trials (CONSORT) statement. 419 
5. Conclusions 420 
The evidence for managing patients with UR/BPO with pharmacological or non-421 
pharmacological treatments is limited. CoE is generally low. There is some evidence that usage 422 
of α1-blockers (alfuzosin and tamsulosin) may improve resolution of UR/BPO. As most non-423 
pharmacological treatments have not been evaluated in patients with UR/BPO, the evidence is 424 
inconclusive about their benefits and harms. 425 
 426 
 427 
 428 
 429 
 430 
 431 
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Legends 432 
Figure 1. PRISMA Flow diagram. Citations in conference abstract form and those written in 433 
non-English language were excluded. 434 
Figure 2. Risk of Bias assessment of included studies (Red: High risk of bias; Yellow: Unclear 435 
risk of bias; Green: Low risk of bias). A) RCTs. B) non-RCTs prospective comparative studies) 436 
Figure 3. Alfuzosin vs placebo; Successful TWOC rate at TWOC  437 
Figure 4. Tamsulosin vs placebo; Successful TWOC rate at TWOC 438 
Supplementary Material 1. Appendix 1: Literature search strategy 439 
Supplementary Material 2. PROSPERO protocol (Protocol number: CRD42017077152) that 440 
includes detailed information about how the SR process was handled; including data extraction, 441 
data analysis, data synthesis, and sub-group analysis. 442 
Supplementary Material 3. M-TURP vs B-TURP in catheterized patients (Tables 2-4)  443 
Supplementary Material 4. Forests plots showing all pooled estimates of effects calculated in 444 
this SR (at least two RCTs included)  445 
Supplementary Material 5. Summary of findings tables (all comparisons) 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
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 456 
Abbreviations  457 
5ARI: 5α reductase inhibitor 458 
ALFAUR: Alfuzosin in Acute Urinary Retention  459 
AUR: Acute Urinary Retention 460 
B-TURP: Bipolar Transurethral Resection of the Prostate  461 
BPO: Benign Prostatic Obstruction 462 
CI: Confindence Interval  463 
CoE: Certainty of Evidence  464 
COMET: Core Outcome Measures in Effectiveness Trials 465 
CONSORT: Consolidated Standards of Reporting Trials  466 
COS: Core Outcome Set  467 
CUR: Chronic Urinary Retention 468 
EAU: European Association of Urology 469 
EMA: European Medicines Agency 470 
FDA: Food and Drug Administration 471 
GDT: GRADEpro Guideline Development Tool 472 
GRADE: Grading of Recommendations Assessment, Development, and Evaluation   473 
IPSS: International Prostate Symptom Score  474 
LUTS: Lower Urinary Tract Symptoms 475 
M-TURP: Monopolar Transurethral Resection of the Prostate 476 
MD: Mean Difference  477 
OD: Once Daily 478 
OR: Odds Ratio 479 
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PDE5I: Phosphodiesterase 5 Inhibitor 480 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses  481 
PVR: Post void Residual Urine Volume  482 
Qmax: Maximum Flow Rate  483 
QoL: Quality of Life 484 
QRCT: Quasi-Randomized Control Trial 485 
RCT: Randomized Control Trial 486 
RoB: Risk of Bias  487 
SM: Supplementary Material  488 
SoF: Summary of Findings  489 
SPC: Suprapubic Catheterization 490 
SR: Systematic Review 491 
TUMT: Transurethral Microwave Thermotherapy  492 
TURP: Transurethral Resection of the Prostate  493 
TWOC: Trial Without Catheter  494 
UR: Urinary Retention  495 
UR/BPO: Urinary Retention secondary to Benign Prostatic Obstruction 496 
UTI: Urinary Tract Infection 497 
WHO ICTRP: World Health Organization International Clinical Trials Registry Platform  498 
 499 
 500 
 501 
 502 
 503 
  
22 
 
 504 
References 505 
[1] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower 506 
urinary tract function: report from the Standardisation Sub-committee of the International 507 
Continence Society. Neurourol Urodyn 2002;21:167-78. 508 
[2] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower 509 
urinary tract function: report from the Standardisation Sub-Committee of the International 510 
Continence Society. Urology 2003;61:37-49. 511 
[3] Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and 512 
post-void residual urine in men: separating truth from tradition. J Urol 2008;180:47-54. 513 
[4] Oelke M, Speakman MJ, Desgrandchamps F, Mamoulakis C. Acute Urinary Retention 514 
Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms 515 
Participating in Pharmacotherapy Trials: A Literature Review. Urology 2015;86:654-65. 516 
[5] Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom 517 
MC. Low incidence of acute urinary retention in the general male population: the triumph 518 
project. Eur Urol 2005;47:494-8. 519 
[6] Agrawal MS, Yadav A, Yadav H, Singh AK, Lavania P, Jaiman R. A prospective 520 
randomized study comparing alfuzosin and tamsulosin in the management of patients 521 
suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol 522 
2009;25:474-8. 523 
[7] McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-524 
release alfuzosin and trial without catheter after acute urinary retention: a prospective, 525 
placebo-controlled. BJU Int 1999;84:622-7. 526 
  
23 
 
[8] Shah T, Palit V, Biyani S, Elmasry Y, Puri R, Flannigan GM. Randomised, placebo 527 
controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter 528 
following acute urinary retention. Eur Urol 2002;42:329-32. 529 
[9] Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in 530 
acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354-7. 531 
[10] Kumar S, Tiwari DP, Ganesamoni R, Singh SK. Prospective randomized placebo-532 
controlled study to assess the safety and efficacy of silodosin in the management of acute 533 
urinary retention. Urology 2013;82:171-5. 534 
[11] McNeill SA, Hargreave TB. Alfuzosin once daily facilitates return to voiding in 535 
patients in acute urinary retention. J Urol 2004;171:2316-20. 536 
[12] Taube M, Gajraj H. Trial without catheter following acute retention of urine. Br J Urol 537 
1989;63:180-2. 538 
[13] Breum L, Klarskov P, Munck LK, Nielsen TH, Nordestgaard AG. Significance of 539 
acute urinary retention due to intravesical obstruction. Scand J Urol Nephrol 1982;16:21-4. 540 
[14] Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic 541 
obstruction-what's the long-term effectiveness of medical therapies? Eur Urol 2001;39 Suppl 542 
3:20-5. 543 
[15] Kuiper JG, Bezemer ID, Driessen MT, et al. Rates of prostate surgery and acute 544 
urinary retention for benign prostatic hyperplasia in men treated with dutasteride or 545 
finasteride. BMC Urol 2016;16:53. 546 
[16] Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with 547 
dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic 548 
hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31. 549 
  
24 
 
[17] Pickard R, Emberton M, Neal DE. The management of men with acute urinary 550 
retention. National Prostatectomy Audit Steering Group. Br J Urol 1998;81:712-20. 551 
[18] Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 552 
1997;11:609-22. 553 
[19] Brasure M, Fink HA, Risk M, et al.  Chronic Urinary Retention: Comparative 554 
Effectiveness and Harms of Treatments. Rockville (MD) 2014. 555 
[20] Fisher E, Subramonian K, Omar MI. The role of alpha blockers prior to removal of 556 
urethral catheter for acute urinary retention in men. Cochrane Database Syst Rev 557 
2014:Cd006744. 558 
[21] Yoon PD, Chalasani V, Woo HH. Systematic review and meta-analysis on 559 
management of acute urinary retention. Prostate Cancer Prostatic Dis 2015;18:297-302. 560 
[22] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new 561 
proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 562 
2004;240:205-13. 563 
[23] Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified 564 
Clavien classification system: a standardized platform for reporting complications in 565 
transurethral resection of the prostate. World J Urol 2011;29:205-10. 566 
[24] Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the 567 
quality of evidence. J Clin Epidemiol 2011;64:401-6. 568 
[25] Moher DL, A. Tetzlaff, J. Altman, DG. Prisma Group. Preferred reporting items for 569 
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. 570 
[26] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting 571 
systematic reviews and meta-analyses of studies that evaluate health care interventions: 572 
explanation and elaboration. PLoS Med 2009;6:e1000100. 573 
  
25 
 
[27] Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of 574 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available 575 
from www.handbook.cochrane.org. 576 
[28] Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of 577 
evidence-inconsistency. J Clin Epidemiol 2011;64:1294-302. 578 
[29] Knoll T, Omar MI, Maclennan S, et al. Key Steps in Conducting Systematic Reviews 579 
for Underpinning Clinical Practice Guidelines: Methodology of the European Association of 580 
Urology. Eur Urol 2018;73:290-300. 581 
[30] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-582 
analyses. BMJ 2003;327:557-60. 583 
[31] Al-Hashimi MMR. Alfuzosin 10 mg Once Daily in the Management of Acute Urinary 584 
Retention of Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled Study. 585 
Current Urology 2007;1:28-34. 586 
[32] Hassan S, El-Ebiary M, Mabrouk M. Early versus late trail of catheter removal in 587 
patients with urinary retention secondary to benign prostatic hyperplasia under tamsulosin 588 
treatment. Urol Sci 2018;29:288-92. 589 
[33] Kara O, Yazici M. Is the double dose alpha-blocker treatment superior than the single 590 
dose in the management of patients suffering from acute urinary retention caused by benign 591 
prostatic hyperplasia? Urol J 2014;11:1673-7. 592 
[34] Maldonado-Avila M, Manzanilla-Garcia HA, Sierra-Ramirez JA, et al. A comparative 593 
study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after 594 
transurethral catheter removal in patients with benign prostatic growth. Int Urol Nephrol 595 
2014;46:687-90. 596 
  
26 
 
[35] Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin in 597 
the management of acute urinary retention secondary to benign prostatic hyperplasia in 598 
patients planned for trial without catheter. A prospective randomized study. Cent European J 599 
Urol 2017;70:259-63. 600 
[36] Prieto L, Romero J, Lopez C, Ortiz M, Pacheco JJ. Efficacy of doxazosin in the 601 
treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 2008;81:66-602 
71. 603 
[37] Sharifi SH, Mokarrar MH, Khaledi F, Yamini-Sharif R, Lashay A, Soltani MH. Does 604 
sildenafil enhance the effect of tamsulosin in relieving acute urinary retention? Int Braz J Urol 605 
2014;40:373-8. 606 
[38] Tiong HY, Tibung MJ, Macalalag M, Li MK, Consigliere D. Alfuzosin 10 mg once 607 
daily increases the chances of successful trial without catheter after acute urinary retention 608 
secondary to benign prostate hyperplasia. Urol Int 2009;83:44-8. 609 
[39] Ghalayini IF, Al-Ghazo MA, Pickard RS. A prospective randomized trial comparing 610 
transurethral prostatic resection and clean intermittent self-catheterization in men with chronic 611 
urinary retention. BJU Int 2005;96:93-7. 612 
[40] Mamoulakis C, Schulze M, Skolarikos A, et al. Midterm results from an international 613 
multicentre randomised controlled trial comparing bipolar with monopolar transurethral 614 
resection of the prostate. Eur Urol 2013;63:667-76. 615 
[41] Schelin S, Geertsen U, Walter S, et al. Feedback microwave thermotherapy versus 616 
TURP/prostate enucleation surgery in patients with benign prostatic hyperplasia and 617 
persistent urinary retention: a prospective, randomized, controlled, multicenter study. Urology 618 
2006;68:795-9. 619 
  
27 
 
[42] Zhengyong Y, Changxiao H, Shibing Y, Caiwen W. Randomized controlled trial on 620 
the efficacy of bladder training before removing the indwelling urinary catheter in patients 621 
with acute urinary retention associated with benign prostatic hyperplasia. Scand J Urol 622 
2014;48:400-4. 623 
[43] Guazzoni G, Montorsi F, Bergamaschi F, Consonni P, Bellinzoni P, Rigatti P. 624 
Prostatic spiral versus prostatic urolume wallstent for urinary retention due to benign prostatic 625 
hyperplasia. A long-term comparative study. Eur Urol 1993;24:332-6. 626 
[44] Horgan AF, Prasad B, Waldron DJ, O'Sullivan DC. Acute urinary retention. 627 
Comparison of suprapubic and urethral catheterisation. Br J Urol 1992;70:149-51. 628 
[45] Patel MI, Watts W, Grant A. The optimal form of urinary drainage after acute 629 
retention of urine. BJU Int 2001;88:26-9. 630 
[46] Mamoulakis C, Skolarikos A, Schulze M, et al. Results from an international 631 
multicentre double-blind randomized controlled trial on the perioperative efficacy and safety 632 
of bipolar vs monopolar transurethral resection of the prostate. BJU Int 2012;109:240-8. 633 
[47] Mamoulakis C, Skolarikos A, Schulze M, et al. Bipolar vs monopolar transurethral 634 
resection of the prostate: evaluation of the impact on overall sexual function in an 635 
international randomized controlled trial setting. BJU Int 2013;112:109-20. 636 
[48] Cetti RJ, Hicks JA, Venn SN, Carter PG, Britton JP. Results from an international 637 
multicentre double-blind randomized controlled trial on the perioperative efficacy and safety 638 
of bipolar vs monopolar transurethral resection of the prostate. BJU Int 2012;109:E38; author 639 
reply E-40. 640 
[49] Kidd EA, Stewart F, Kassis NC, Hom E, Omar MI. Urethral (indwelling or 641 
intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. 642 
Cochrane Database Syst Rev 2015:Cd004203. 643 
  
28 
 
[50] Gravas S., Cornu J.N., Drake M.J., et al.; members of the EAU Guidelines on the 644 
Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign 645 
Prostatic Obstruction (BPO). Edn. presented at the EAU Annual Congress Copenhagen 2018. 646 
978-94-92671-01-1. Place published: Arnhem, The Netherlands.: Publisher: EAU Guidelines 647 
Office. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. 648 
 649 
